Innovative Pharmaceutical Biotech (HKSE:00399) ROCE % : 104.43% (As of Sep. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Innovative Pharmaceutical Biotech ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Innovative Pharmaceutical Biotech's annualized ROCE % for the quarter that ended in Sep. 2023 was 104.43%.

Innovative Pharmaceutical Biotech ROCE % Historical Data

The historical data trend for Innovative Pharmaceutical Biotech's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovative Pharmaceutical Biotech ROCE % Chart

Innovative Pharmaceutical Biotech Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

ROCE %

Get a 7-Day Free Trial

-8.03

-5.21

-2.17

23.86

-2.70

Innovative Pharmaceutical Biotech Semi-Annual Data
	Dec13	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
ROCE %	Get a 7-Day Free Trial															49.23	-1.46	-1.65	-6.49	104.43

Innovative Pharmaceutical Biotech ROCE % Calculation

Innovative Pharmaceutical Biotech's annualized ROCE % for the fiscal year that ended in Mar. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	-20.702	/	( ( (1394.996 - 99.772)	+	(1384.048 - 1147.044) )	/ 2 )
	=	-20.702	/	( (1295.224	+	237.004)	/ 2 )
	=	-20.702	/	766.114
	=	-2.70 %

Innovative Pharmaceutical Biotech's ROCE % of for the quarter that ended in Sep. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2023 )		(Q: Mar. 2023 )		(Q: Sep. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2023 )		(Q: Mar. 2023 )		(Q: Sep. 2023 )
	=	648.11	/	( ( (1384.048 - 1147.044)	+	(1382.219 - 377.972) )	/ 2 )
	=	648.11	/	( ( 237.004	+	1004.247 )	/ 2 )
	=	648.11	/	620.6255
	=	104.43 %

(1) Note: The EBIT data used here is two times the semi-annual (Sep. 2023) EBIT data.

Innovative Pharmaceutical Biotech (HKSE:00399) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Innovative Pharmaceutical Biotech ROCE % Related Terms

Thank you for viewing the detailed overview of Innovative Pharmaceutical Biotech's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovative Pharmaceutical Biotech (HKSE:00399) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Innovative Pharmaceutical Biotech Ltd (HKSE:00399) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

168-200 Connaught Road Central, Unit No. 2111, 21st Floor, Sheung Wan, West Tower Shun Tak Centre, Hong Kong, HKG

Website

http://www.ipb.asia

Innovative Pharmaceutical Biotech Ltd is focused on developing an insulin product that could be administered orally. It has two primary segments of business: the research and development of pharmaceutical products and the trading of beauty products. It generates maximum revenue from trading in the beauty products segment.

Executives

Mao Yumin	2101 Beneficial owner
Extrawell Pharmaceutical Holdings Limited
Chau Yiu Ting	2101 Beneficial owner
Mao Yumin	2101 Beneficial owner
Chau Yiu Ting	2101 Beneficial owner

Innovative Pharmaceutical Biotech (HKSE:00399) Headlines

No Headlines